There are significant disparities with regards to incidence, timely diagnosis, access to
treatment, clinical trial participation and health care utilization that negatively impact …

Background: Wide disparities in health status exist in the United States across race and
ethnicity, broadly driven by social determinants of health—most notably race and ethnic …

Multiple myeloma (MM) incidence, mortality, and survival vary by race and ethnicity, but the
causes of differences remain unclear. We investigated demographic, clinical, and molecular …

Survival in multiple myeloma has improved significantly in recent years, especially in young
patients. We reviewed the evolution of the survival of patients with MM in three groups based …

There is a critical need for equitable access to cell therapies in cancer treatment, particularly
within public safety-net healthcare systems that serve minority and socioeconomically …

In this issue of Blood Cancer Journal, Ailawadhi et al. explored the sociodemographic
variables impacting differences in access and utilization of autologous stem cell …

Recent insight in the genomic landscape of newly diagnosed multiple myeloma (NDMM)
and its precursor conditions, monoclonal gammopathy of uncertain significance (MGUS) …

Background Upfront high-dose therapy (HDT) followed by autologous stem cell
transplantation (ASCT) remains a profitable strategy for newly diagnosed multiple myeloma …

Multiple myeloma (MM) accounts for 10% of hematologic cancers in the US; however,
incidence and mortality occur disproportionately between racial groups in real-world …

Myeloma is one of the most common types of haematological malignancies. We aimed to
investigate the incidence rates of myeloma by sex, race, age, and histological subgroups in …